Another great turnout for the May 13 meeting which featured a presentation by Naveen Bangia, PhD; Director, Scientific Affairs for the The Binding Site Inc. He discussed Lab Values and how Binding Site tests, Freelite and Heavylite, help doctors and researches tailor more individualized therapies.
Dr. Bangia shared an incredibly informative slide presentation covering a brief history of Myeloma, how Myeloma is created, how it spreads, and what tools we have to detect it.
- Multiple Myeloma means: Multiple = many, Myeloma = marrow so Multiple Myeloma is many marrow tumors.
- Multiple Myeloma is a Monoclonal Antibody which means “one copy” antibody. Instead of producing a wide range of antibodies plasma cells produce only one damaged antibody.
- Every Myeloma patient has had MGUS at some point. MGUS doesn’t always progress to Myeloma but if you have MGUS you stand a 1% per year chance of having it progress to Myeloma.
- Healthy B-cells become healthy plasma cells but damaged B-cells can produce Myeloma cells.
- There are links between light chain and heavy chain proteins. Among Myeloma patients 80% can be tracked through intact Ig, 15-20% express through a light chain, and 1-5% have oligosecretory (almost nonexistent) or nonsecretory versions of the disease.
- Understand the CRAB and SLiM Myeloma diagnosis criteria.